New York, Feb 22, 2026, 12:09 EST — The market has closed.
- Lilly shares slipped on Friday, lagging behind a wider Wall Street upswing.
- Next week, traders are zeroed in on fresh hints about pricing and supply for obesity drugs.
- On deck: a March conference spot, plus an FDA call slated for April.
Shares of Eli Lilly and Company (LLY) slipped 1.34% Friday, settling at $1,009.52 before U.S. markets headed into the weekend.
Lilly’s drop stands out. The company is now seen as a pure gauge for the obesity-drug trade—demand is strong, expectations are high, but there’s little leeway for error. Priced for growth, the stock tends to react quickly even to minor sentiment changes.
Investors are rethinking macro risk, too. Policy headlines jolt markets, sometimes pushing money into big-cap defensives when rotations hit.
The S&P 500 climbed 0.69% Friday, with the Nasdaq up 0.90%, after the U.S. Supreme Court tossed out President Donald Trump’s global tariffs. New figures pointed to slower growth and hotter inflation. “Today is a removal of some uncertainty,” said Mike Dickson, Horizon Investments’ head of research and quantitative strategies. Reuters
Lilly’s immediate focus remains squarely on GLP-1 drugs — treatments that act like gut hormones to lower blood sugar and suppress appetite — plus the pipeline of next-gen products aiming to expand the market. According to a recent filing, Lilly is sitting on $1.5 billion in pre-launch inventory of orforglipron, its experimental oral weight-loss drug, ahead of an anticipated FDA decision in April. Meanwhile, Novo Nordisk rolled out its once-daily weight-loss pill in the U.S. just earlier this month. Prescriptions shot past 26,000 in the second full week, based on IQVIA data cited by an analyst.
Regulatory pressure is picking up. On Feb. 6, the FDA announced plans to clamp down on GLP-1 active ingredients showing up in mass-marketed compounded drugs that aren’t approved. The agency warned companies: fix violations or face possible legal moves, including seizures and injunctions.
Lilly investors are looking ahead to March 2, when CFO Lucas Montarce is set for a fireside chat at TD Cowen’s annual health care conference. The event gets webcast via the company’s investor site.
The road isn’t smooth. Pricing pressure on obesity drugs, changing reimbursement policies, and even small signs of renewed supply constraints could dent sentiment. Competition isn’t standing still either—Novo Nordisk faces a growing field.
Lilly’s stock is trading roughly 11% under its 52-week peak of $1,133.95 from Jan. 8. Volume on Friday hit about 3.2 million shares, lining up with the 50-day average. The stock beat out Johnson & Johnson and Pfizer for the session, while AbbVie finished up just a bit, according to MarketWatch data.
Monday’s open puts the focus on whether Friday’s risk-on mood has staying power—and if Lilly manages to keep the obesity-drug story climbing into its March 2 conference appearance, with the FDA’s orforglipron decision still looming in April.
